US patent issued for use of BCM-95 Curcumin for Alzheimers disease

Found to be highly beneficial in preventing further cognitive decline, reducing amyloid beta plaques, increasing vitamin E levels in the body, and enhancing curcumin levels in blood

BCM-95 Curcumin, the patented turmeric extract formulation from Indian company Arjuna Natural Extracts, has received a US patent for its use as a potential treatment for Alzheimer’s disease. The patent describes the unique combination of beneficial curcuminoids and turmeric essential oil in BCM-95, as well as its enhanced absorption and bioavailability.

BCM-95 Curcumin has already undergone human clinical trials in patients with Alzheimer’s disease at Chinese University of Hong Kong under Professor Larry Baum (2008). It was found to be highly beneficial in preventing further cognitive decline, reducing amyloid beta plaques, one of the major causes of Alzheimer’s disease, increasing vitamin E levels in the body, and enhancing curcumin levels in blood.

Under researcher Professor Ralph Martins in Australia, BCM-95 Curcumin is also undergoing two other human clinical trials in patients with Alzheimer’s disease and in subjects at risk of developing the condition.

‘These research findings will open a new world of hope to the millions battling Alzheimer’s every day,’ said Benny Antony, Joint MD of Arjuna Natural Extracts, based in Kerala, India, and the inventor of BCM-95.

BCM-95 Curcumin is also being studied for various indications including inflammation, arthritis, diabetes, depression, cancer prevention and treatment, as an adjuvant to chemotherapy and cancer radiation, and in liver and gastrointestinal diseases.

Companies